Stay Curious. Stay Connected.
MailNewsletters♡Donate Now
Sign up
*Password must be at least 8 characters and contain one uppercase letter, one lowercase letter, one number and one symbol.
Already have an account?
By submitting, you consent that you are at least 18 years of age and to receive information about MPR's or APMG entities' programs and offerings. The personally identifying information you provide will not be sold, shared, or used for purposes other than to communicate with you about MPR, APMG entities, and its sponsors. You may opt-out at any time clicking the unsubscribe link at the bottom of any email communication. View our Privacy Policy.
Sign in to your profile
Forgot Password?
New to MPR News?
Welcome back
to news
for you
Reset Password

Enter the username on file and we'll send you a code to reset your password.

Still require assistance or not sure what your User Name is?
Welcome back
to news
for you
Email Verification

A verification code has been emailed to

Still awaiting the code?
St. Paul, Minn.

Boston Scientific stent issue resolved

Go Deeper.

Create an account or log in to save stories.

Log inCreate a free Account

Like this?

Thanks for liking this story! We have added it to a list of your favorite stories.

Show me!

Boston Scientific has resolved all issues that prompted a 2006 corporate warning letter from the Food and Drug Administration concerning the company's heart stents.

Stents are minute mesh tubes that prop open clogged arteries. In 2006, the FDA cited Boston Scientific for violations in the manufacturing of cardiovascular devices including the Taxus stent, which generated nearly half of its revenue.

The FDA lifted restrictions on the company earlier this year. Boston Scientific said the agency has now declared its plants in compliance with quality systems regulations.

In a statement, Boston Scientific president and Chief executive Ray Elliott said the resolution of the corporate warning letter "marks a major milestone."